EcoDrugPlus

Nicastrin

Ensembl ID : ENSMLUG00000001333
Gene Symbol: NCSTN
2 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSMLUG00000003973
Gene Symbol: NAMPT
2 Cross references
235 Possible Orthologues:

Nischarin

Ensembl ID : ENSMLUG00000015362
Gene Symbol: NISCH
2 Cross references
209 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSMLUG00000005748
Gene Symbol: NOTCH1
2 Cross references
273 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSMLUG00000004827
Gene Symbol: NOTCH3
2 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSMLUG00000005986
Gene Symbol: NFKB1
2 Cross references
200 Possible Orthologues:

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSMLUG00000006287
Gene Symbol: NFKB2
2 Cross references
124 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSMLUG00000004897
Gene Symbol: NR1H2
2 Cross references
305 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSMLUG00000017646
Gene Symbol: NR1H3
2 Cross references
391 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSMLUG00000009273
Gene Symbol: NR1H4
2 Cross references
387 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSMLUG00000011289
Gene Symbol: NR3C1
2 Cross references
278 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSMLUG00000008108
Gene Symbol: NR3C2
2 Cross references
212 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).